News

South Africa’s Biovac Opens mRNA Lab Backed by Gates Foundation

South Africa’s Biovac Opens mRNA Lab Backed by Gates Foundation
Saturday, 08 November 2025 18:09
  • Biovac opens mRNA-capable vaccine lab in Cape Town, backed by global donors
  • Facility enables full vaccine production, supporting Africa’s health sovereignty goals
  • Project aligns with AU plan to boost local vaccine output to 60% by 2040

The facility will support full vaccine and therapeutic manufacturing for diseases prevalent in Africa. The Cape Town facility is funded by the Gates Foundation, the European Union, and the German government.

Biovac said the lab will allow it to produce vaccines from early development through final formulation using advanced technologies such as messenger RNA (mRNA). It is also expected to make other treatments while fostering innovation and developing homegrown intellectual property.

Advancing African Vaccine Self-Sufficiency

The laboratory includes infrastructure for developing, screening, evaluating, and producing mRNA drug substances. It also houses a specialized suite for nanoparticle formulation, which encapsulates and protects mRNA, as well as dedicated spaces for bacterial and cell culture, cell bank storage, and handling sensitive biological materials.

The establishment of our new product development laboratory is a major milestone for Biovac and for African vaccines and vaccine innovation. It gives us the capability to develop and test next-generation vaccines using the most advanced technology available, ensuring that Africa is not left behind in responding to current and future vaccine-preventable diseases,” said Biovac CEO Morena Makhoana.

Mark Suzman, CEO of the Gates Foundation, said the lab “brings the promise of faster, more reliable access to lifesaving vaccines – developed and produced in Africa, for Africa.”

Aligning with Continental Goals

The project supports the African Union’s plan to raise Africa’s share of locally produced vaccines from 1% to 60% by 2040 to strengthen health security. The AU aims to reach that target with support from member states, donors, multilateral lenders, and private-sector initiatives like Biovac’s.

Biovac, 47.5% owned by two South African government agencies, supplies vaccines for the country’s childhood immunization program. It was founded to distribute imported vaccines for the Department of Health before gradually building capacity for final-stage manufacturing, or “fill and finish.”

The company provides vaccines in South Africa for tuberculosis, tetanus, diphtheria, polio, Haemophilus influenzae, and hepatitis B. During the COVID-19 pandemic, Biovac partnered with Pfizer and BioNTech to produce vaccines for the African Union.

Walid Kéfi

 
On the same topic
Africa holds 3% of global solar PV jobs but posts fastest 23% growth Utility-scale and off-grid solar drive new roles in installation, sales and...
The US, DRC and Rwanda sign a new framework tying mineral access, governance reforms and security cooperation into one strategic agreement. The...
Ghana aims to lead Africa in electric vehicle development, minister says Country has 17,000 EVs but lacks nationwide charging and maintenance...
• Boeing projects Africa’s aircraft fleet to double to 1,680 units by 2044• Passenger traffic expected to grow 6% annually, driven by urbanization and...
Most Read
01

Camtel to launch Blue Money in 2026, entering Cameroon’s crowded mobile money market led by MTN Mo...

Cameroon: State Owned Telecommunication Company To Enter Mobile Money Market
02

Francophone Sub-Saharan Africa hosts 860+ startups but faces deep structural weaknesses EY urges...

Major Tech Reforms Needed for Francophone SSA to Attract More Investment, Report Says
03

Kossi Ténou succeeds Badanam Patoki as president of the AMF-UMOA. Ténou brings over 20 years of e...

Togo’s Kossi Ténou Appointed President of AMF-UMOA
04

This week in African health news: Global measles cases have dropped nearly 80 percent since 2000, bu...

Measles Cases Drop 80%, Ethiopia's Marburg Response and Cholera in DRC (Weekly Health Update)
05

Maersk will resume transit through the Suez Canal from December 2025 after a two-year diversion. ...

Maersk to Resume Suez Canal Transit in December
Enter your email to receive our newsletter

Ecofin Agency provides daily coverage of nine key African economic sectors: public management, finance, telecoms, agribusiness, mining, energy, transport, communication, and education.
It also designs and manages specialized media, both online and print, for African institutions and publishers.

SALES & ADVERTISING

regie@agenceecofin.com 
Tél: +41 22 301 96 11 
Mob: +41 78 699 13 72


EDITORIAL
redaction@agenceecofin.com

More information
Team
Publisher

ECOFIN AGENCY

Mediamania Sarl
Rue du Léman, 6
1201 Geneva
Switzerland

 

Ecofin Agency is a sector-focused economic news agency, founded in December 2010. Its web platform was launched in June 2011. ©Mediamania.

 
 

Please publish modules in offcanvas position.